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Liver progenitor cells (LPCs) can proliferate extensively, are able to differentiate into hepatocytes and cholangiocytes, and contribute
to liver regeneration. The presence of LPCs, however, often accompanies liver disease and hepatocellular carcinoma (HCC),
indicating that they may be a cancer stem cell. Understanding LPC biology and establishing a sensitive, rapid, and reliable method
to detect their presence in the liver will assist diagnosis and facilitate monitoring of treatment outcomes in patients with liver
pathologies. A transcriptomic meta-analysis of over 400 microarrays was undertaken to compare LPC lines against datasets of
muscle and embryonic stem cell lines, embryonic and developed liver (DL), and HCC. Three gene clusters distinguishing LPCs
from other liver cell types were identified. Pathways overrepresented in these clusters denote the proliferative nature of LPCs and
their association with HCC. Our analysis also revealed 26 novel markers, LPC markers, including Mcm2 and Ltbp3, and eight
known LPCmarkers, includingM2pk andNcam.These markers specified the presence of LPCs in pathological liver tissue by qPCR
and correlated with LPC abundance determined using immunohistochemistry.These results showcase the value of global transcript
profiling to identify pathways and markers that may be used to detect LPCs in injured or diseased liver.
1. Introduction
Liver progenitor cells (LPCs) have garnered substantial
interest in the field of liver biology due to their enormous
regenerative capacity [1, 2] which positions LPCs as a strong
candidate for cell therapy to treat liver disease. Whilst their
link to liver disease [3–5] and potential as a liver cancer stem
cell constrain their utility, they afford a model to investigate
the molecular and cellular mechanisms that underlie tumori-
genic transformation.
Inmany chronic liver diseases, when proliferation of hep-
atocytes is limited, LPCs replicate and differentiate, providing
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an alternate source of hepatocytes needed for regeneration
[6]. This “LPC response” is observed in humans in cases
of alcoholic liver disease, hemochromatosis, hepatitis C and
B infection, and HCC [4, 5, 7–9]. Other liver pathologies
may also involve expansion of LPCs; however, their role in
these instances is undefined [10]. A rodent model of chronic
liver disease, the choline-deficient, ethionine-supplemented
(CDE) diet which results in fatty liver and subsequently
fibrosis and cirrhosis, induces LPCs in rats [11] and mice
[12] and has been used extensively for studying LPCs. This
model was used to reveal Wnt and Notch-controlled signal-
ing that specifies LPCs to the hepatocytic and cholangio-
cytic lineages, respectively [13]. Other strategies to induce
LPCs include administration of 3,5-diethoxy-carbonyl-1,4-
dihydrocollidine (DDC) [11] and acetyl aminofluorene to
block hepatocyte proliferation followed by partial hepatec-
tomy [14] and administration of alkylating agents, monocro-
taline [15] or retrorsine [16].
The degree towhich LPCs contribute to liver regeneration
is controversial. In contrast to several publications that
specify a role for LPCs in liver regeneration [6, 17, 18], a
recent review [19] highlighted lineage-tracing studies [20, 21]
in which LPCs did not. This discordance may be dependent
on the method used to induce liver pathology. Nevertheless,
using different approaches, several laboratories have estab-
lished LPC lines that are capable of in vitro differentiation into
cholangiocytes and hepatocytes [22–25].
LPCs are a heterogeneous cell population and whether
LPCs induced by different etiologies and via various mod-
els are identical or even share similar genetic profiles is
unknown. Comparing lines generated in different labora-
tories thus mandates caution when interpreting findings to
reach generalized conclusions on the biology of LPCs. These
issues are compounded as current LPC markers often stain
cholangiocytes as well, highlighting a requirement for addi-
tional markers.
Proliferation of LPCs and development of liver cancer
have been correlated. In mice, inducible liver-specific expres-
sion of c-myelocytomatosis (c-Myc) oncogene stimulated
proliferation of an immature cell population resulting inHCC
[26]. Upon c-Myc inactivation, tumor cells differentiated
into hepatocytes and cholangiocytes, suggesting the HCCs
formed fromLPC-like cells. FibrolamellarHCCs are enriched
with cancer stem cells resembling “biliary tree stem cells,”
LPC precursors [27]. In another study, comprehensive gene
array analysis of human HCC identified gene amplification
of yes-associate protein (YAP) and cellular inhibitor of apop-
tosis (cIAP1) as potential oncogenes [28]. In the same study,
overexpression of cIAP1 in a p53 null LPC cell line substan-
tially reduced tumor onset time and increased tumor burden.
Additional links between theHippo pathway, LPCs, andHCC
development have been identified [29–31]. High YAP expres-
sion marks progenitor cells within the liver and expression
within hepatocytes is sufficient to differentiate them into
LPC-like cell [32].Thismay have implications forHCCdevel-
opment, especially for tumors described as poorly differenti-
ated. It is therefore of interest to obtain a transcript profile
of LPCs, both to aid discovery of markers for detection and
to further study their association with HCC. We hypothesize
that LPCs will display a transcript profile that reflects some,
if not many, of the “hallmarks” of cancer, in particular,
dysregulated cell proliferation and resistance to cell death
[33].
In this study, we performed transcriptome analysis of
established andwell-characterized LPC lines and pooled LPC
transcriptome data from many laboratories to determine
whether LPCs isolated by different groups using different
approaches are similar or distinguishable based on their tran-
scriptome. Additionally, we interrogated several repositories
of transcriptome data for comparison with other cell and
tissue types including datasets of muscle and embryonic stem
cell lines, embryonic and developed liver, andHCC.We iden-
tified signaling pathways and promoters that are consistently
active in LPC lines to provide greater insight into their biol-
ogy. Lastly, we identified novel LPC markers and validated
their utility to identify LPCs in different mouse models of
liver pathology.
2. Materials and Methods
2.1. Capturing the Transcriptomes. The LPC lines were
derived by different procedures in multiple laboratories.
Bipotential murine embryonic liver (BMEL) cell lines were
derived from CBA/J × C57Bl/6J cross embryonic livers at
14 days post coitum. Bipotential murine oval liver (BMOL)
cell lines were derived from 7-week-old male C57BL/6 strain
wild-type mice livers subjected to 3 weeks of CDE diet.
Tokyo-LPC (T-LPC) was isolated by selection of EPCAM+
cells from DDC-injured livers. The p53-immortalized liver
(PIL) 1, 2, 3, 4, and 5 lines were derived from adult p53
null (C57BL/6 strain) mice. These LPC lines have been
characterized previously [22, 23, 25, 34, 35], by morphology,
bipotentiality, proliferative ability, and expression of LPC
markers. For microarrays generated in our laboratory, LPC
RNAwas isolated using TRIzol (Invitrogen) andRNeasymini
kit (Qiagen)withDNase I treatment followingmanufacturer’s
recommendations. RNA quality was verified using an Agilent
2100 Bioanalyser. Synthesis and labeling of cDNA and cRNA,
fragmentation, hybridization, washing, staining, and scan-
ning of the Affymetrix Mouse Genome 430 2.0 GeneChips
including quality control checkswere performed according to
the manufacturer’s instructions.
2.2. Normalization of Microarray Experiments. Microarray
experiments (381) that fulfilled the requirements of hav-
ing at least three replicates performed on the Affymetrix
Mouse Genome 430 2.0 or 430A GeneChips platforms were
downloaded from the National Centre for Biotechnology
Information Gene Expression Omnibus (GEO) Repository.
Datasets included those generated from LPC lines, C2C12
muscle cell lines, embryonic stem cells, DL, HCC, and
embryonic liver. We performed a meta-analysis of 405
microarrays comprising the 381 publically available microar-
rays and 24 LPC microarrays generated by our laboratory,
using the BMOL, T-LPC, and PIL1-5 LPC lines. The arrays
generated from these seven LPC lines have been uploaded
to the GEO (GSE85114). In addition to these seven LPC
lines, our meta-analysis included three separate, publically
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sourced BMEL lines. A summary of details pertaining to all
arrays used in this manuscript is included in Supplemen-
tary Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/5702873.
Probe sets from all 405 arrays were filtered to include
only present sets since the proportion of absent ones can
considerably affect the data median. Presence for a sample
was established following MAS (MicroArray Suite) 5.0 sum-
marization (𝑝 value < 0.05) when the probe set was present
in at least 75% of replicates. The median gene expression
and Median Absolute Deviation (MAD) were determined
for each microarray, as a representation of the spread of the
data. Median standardization of data involved subtracting
the median array expression from the expression of each
probe set and then dividing the result by the MAD of each
microarray.This produces a median of 0 for each microarray.
Values were thenmultiplied by 500 to increase the spread and
standardize to a common spread that is within the observed
range ofMAD formost of themicroarrays. Finally, a constant
of 750 was added to the values to increase the median to 750,
also within the observed range of medians.
As the Mouse Genome 430 2.0 GeneChip contains more
probes than the 430A GeneChip, the dataset was truncated
to include only the 430A probes. log 2 transformation and
quantile normalization were performed to standardize the
distribution of the probe set intensities to an appropriate
scale.
2.3.Microarray Analysis. Analysis of Variance (ANOVA)was
performed to identify genes with differing means between
more than two groups of conditions [36]. Partek (Missouri,
USA) was used to incorporate contrasts within ANOVA,
prioritizing the comparison of LPCs to other cell types. Genes
with 𝑝 values less than 0.01 were considered differentially
expressed.
Principal component analysis (PCA) [37] was performed
using Partek to visualize the natural grouping of the arrays
based on global gene expression data. The three principal
components that captured most differences were displayed
in three-dimensional scatter plots. Similar microarrays are
grouped together and more diverse microarrays are spaced
further apart.
Expression datasets were hierarchically clustered in
Partek under the parameters of complete (>1000 rows)
or average (<1000 rows) linkage, Euclidean distance, and
agglomerative clustering. Unsupervised clustering enabled
relationships between rows and columns to be organized
into tree diagrams without imposing subjective bias on the
number or size of the clusters. Clusters were systematically
colored and selected based on the distances calculated and
displayed in the tree diagram branch arms using the “color
by cluster” function in Partek.
The coefficient of variation was determined for each gene
by dividing the standard deviation of each gene expres-
sion pattern by its average expression value, as previously
described [38], to identify gene expression profiles with
minimal variation across the cell types analyzed. The coef-
ficient of variations and Pearson correlation coefficients were
calculated in Microsoft Excel.
2.4. Pathway and Promoter Analysis. Database for Annota-
tion, Visualization and Integrated Discovery (DAVID) was
used to ascertain overrepresented pathways and perform
gene identifier conversions. The pathway overrepresentation
used an EASE score (a modified Fisher exact test) to calculate
𝑝 values and determine if proportions of the categories
differed [39, 40]. A significance threshold was set to 𝑝 < 0.05.
Only pathways that met a 𝑝 < 0.05 threshold and contained
10 or more genes from the input cluster were included in our
analysis.
Promoter Analysis and Interaction Network Toolset
(PAINT) was used to search for overrepresented transcrip-
tion factor binding elements in gene promoters [41]. The
TransFac public database containing known transcription
factor binding sites was used to search 2000 bases upstream
of the transcriptional start sites of the input Entrez Gene lists.
Other parameters selected were the match filter option set to
minimize false positives, the core similarity threshold set to
1.0, and binding elements searched on both strands of DNA.
2.5. qPCR Analysis to Confirm Presence of Predicted LPC
Markers in Liver Tissue. Mice were subjected to one of four
regimes: 3,5-diethoxy-carbonyl-1,4-dihydrocollidine (DDC,
𝑛 = 4) induced hepatotoxicity, CDE injury (𝑛 = 6), or
one of two transgenic models of immune-mediated hepatitis,
Met-Kb (𝑛 = 3) and 178.3 (𝑛 = 3). Experimental mice
were subjected to the DDC regime for 28 days or 21 days
for the remaining models. Controls (𝑛 = 3, 8, 3, 3, resp.)
were used to contrast gene expression levels. All animal
experiments complied with the guidelines specified by the
National Health and Medical Research Council of Australia.
Total RNAwas extracted from the livers of themice described
above and cDNA was transcribed using Tetro RT reverse
transcriptase (Bioline). TaqMan two-step, real-time quantita-
tive PCR (qPCR) with hydrolysis probes from the Universal
Probe Library and the Light Cycler 480 (LC480) Probe
Mastermix (Roche) was used to quantify mRNA expression.
Genes selected to predict the presence of LPCs in injured
livers were muscle-restricted coiled-coil protein (Murc) from
group 𝛼, latent transforming growth factor beta binding
protein 3 (Ltbp3) and neural cell adhesionmolecule 1 (Ncam1)
from group 𝛽, and minichromosome maintenance deficient
(Mcm2) and pyruvate kinase isozymeM2 (M2pk) from group
𝛾. The expressions of known LPC markers, Cd24a antigen
and Sox9, were also determined. Primer sequences are avail-
able in Supplementary Table 2. Data was analyzed using
the LC480 Relative Quantification Software. A five-point
standard curve was generated for each gene, using pooled
cDNA of each sample. A calibrator sample was also included
in every qPCR experiment, for which each qPCR run was
replicated three times. Data was included when amplification
efficiencies/correlation for the assay was ≥95%. Significant
changes in gene expression were determined by comparing
control to experimental samples using a two-tailed Student’s
𝑡-test. Data are displayed relative to TATA-box associated
factor 4A (Taf4a) mRNA expression and normalized to
controls.
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2.6. Quantifying Liver Progenitor Cell Numbers In Vivo.
Sections of formalin-fixed, paraffin-embedded CDE, DDC,
Met-Kb, and 178.3mouse liverwere dewaxed and stainedwith
hematoxylin and eosin to ascertain liver morphology or were
stained with anti-panCK to determine LPC response. PanCK
staining was achieved by first performing antigen retrieval
using proteinase K (Dako, VIC) before applying a 1 : 400 dilu-
tion of anti-panCK (#Z0622,Dako) overnight at 4∘C. Staining
was processed and visualized with DAB using the LSAB
system (Dako) according to the manufacturer’s instructions.
Stained sections were scanned at 40x magnification using an
Aperio ScanScope XT. The Positive Pixel Count v9.1 algo-
rithmwithin the ImageScope software was used to determine
LPC response a.k.a. “panCK positivity,” the number of pixels
positive for panCK staining as a percentage of total tissue
pixels.
3. Results
3.1. Principal Component Analysis Confirms Successful Nor-
malization of Microarrays. Since many of the microarray
experiments were performed in different laboratories, non-
biological variables resulting in differing gene expression
and transcript abundance are expected.These factors include
chip-to-chip variability, different culture conditions includ-
ing medium additives (e.g., growth factors and serum),
cell density at time of harvest, RNA quality/quantity, and
differences in reagents, kits, and equipment. It was therefore
necessary to normalize the data before comparisons were
made. All rawmicroarray data were subject to identical linear
scaling and normalization to reduce the impact of nonbiolog-
ical factors.
To test the success of this normalization, PCA was
performed and the three principal components that captured
most differences (37.5% of the total variation) in the datasets
were plotted (Figure 1). PC1, PC2, and PC3 captured 19.9%,
11.6%, and 6.0% of variation in the datasets, respectively, and
are shown from three angles to aid in distinguishing each
cell/tissue type cluster (Figures 1(a)–1(c)). Without adequate
normalization, different arrays would likely appear scattered
across the three-dimensional PCA plot. In this instance, the
normalized arrays clearly grouped on the PCA plot according
to tissue type, and differences between tissue types were
greater than those within each grouping. For instance, LPC
lines (orange nodes) clustered closely together and away from
DL microarrays (red nodes). Of all cell/tissue groupings, the
DL and HCC arrays clustered closest together, yet they still
occupied distinct regions. This distinction is best visualized
on the first principal component (PC1), which accounts
for the greatest differences in the analysis (Figure 1(a)).
Crucially all data was generated in an unsupervised manner,
that is, without introducing bias from tissue type. These
findings were demonstrative of successful normalization and
justified subsequent analyses to identify a distinct LPC gene
expression pattern.
3.2. Analysis of Hierarchical Clusters Reveals Distinct LPC
Expression Profiles, Pathways, and Promoters. ANOVA was
applied to the tissue type groupings to distinguish the LPC
transcriptome from other cell types. Analysis identified 8623
differentially expressed probe sets when comparing LPCs to
all other groups. From this dataset, five unique clusters were
identified and named clusters A to E (Figure 2). Cluster A
represents probe sets with equivalent or higher expression in
LPCs compared to other cell types. Cluster B includes probes
that display high variability within similar tissue types and
thus is largely uninformative. Cluster C represents probe sets
with high expression in “immortalized” cell lines including
LPCs, muscle, embryonic stem cells, and embryonic liver
whilst being poorly expressed in DL and HCC. Cluster D
includes probes with higher expression in DL and HCC sam-
ples, and cluster E represents probe sets whose expressions
were highly abundant in the majority of samples. Clusters A,
C, and D presented the greatest differences between LPCs
and other cell/tissue groups and thus were the focus of
further analysis. Figure 2 data is provided as a supplementary
spreadsheet (Figure 2 Matrix).
As evident from the scattered color within each clus-
ter, not all probe sets closely aligned within each cluster.
Stringent filters were applied to more precisely define the
LPC transcriptome. The MAS 5.0 algorithm was applied
to make present/absent calls for probe sets. For clusters A
and C, only probe sets that were present in 90% of LPC
arrays were retained. In contrast, only sets absent in 90%
of LPC arrays were retained for cluster D, since they were
largely absent in LPCs. The DAVID and KEGG pathway
tools were subsequently applied to the truncated cluster
A, C, and D lists to functionally categorize and identify
patterns of biological significance within each. The resulting
overrepresented pathways (𝑝 < 0.05), the number of cluster
genes found (counts), and the total geneswithin each pathway
(pathway total) are shown in Figure 3.
DAVID was able to annotate 254 genes to KEGG path-
ways from the filtered cluster A probe set list. In the overrep-
resentedmitogen-activated protein kinase (MAPK) signaling
pathway there were 25 counts from a MAPK pathway total.
Other cluster A pathways included GnRH signaling, cell
cycle, transforming growth factor- (TGF-) beta signaling,
and epidermal growth factor (EGF) receptor ErbB signaling.
Within this cluster, PAINT analysis identified nuclear factor
(erythroid-derived 2)-like 2 (Nrf2), upstream stimulatory
factor (Usf1), cyclic-AMP response element binding protein
(Creb), and activating transcription factor (Atf1) as predicted
binding elements playing an important role in the coregula-
tion of LPC associated genes.
Using the truncated cluster C probe set list, DAVID anno-
tated 426 genes to KEGG pathways. Overrepresented path-
ways included cell cycle, DNA replication, pyrimidine and
purine metabolism, and p53 signaling pathways (Figure 3).
There were also several overrepresented predicted binding
elements for cluster C including growth factor independent
1 transcription repressor (Gfi1), E2F transcription factor
1 (E2f1), melanocyte-inhibiting factor (Mif ), and cartilage
oligomeric matrix protein (Comp).
Clusters A and C are both highly expressed in LPCs
whereas probe sets in cluster D are lower in LPCs com-
pared to DL and HCC samples (Figure 2). The 90% absent
filtered list for cluster D was annotated to 359 genes and





























Figure 1: Principal component analysis (PCA) displays transcriptome clustering sorted by tissue type. Each node represents the average of
at least 3 microarray replicates and is color-coded according to tissue type. The three principal components that captured most differences in
the datasets are plotted with three different three-dimensional views of the same PCA visualization shown in (a), (b), and (c).


















Figure 2: Hierarchical clustering identifies 5 clusters (A, B, C, D, and E) of distinct gene expression data for liver progenitor cells. ANOVA
was performed to compare liver progenitor cells to all other cell/tissue type groups. The 8,623 probe sets that displayed expression levels
significantly different to LPCs (𝑝 < 0.01) were subsequently clustered according to the parameters of Euclidean distance and complete
linkage.
overrepresented KEGG pathways were involved in funda-
mental liver functions, including immunity, detoxification,
and lipid metabolism. Some of these pathways were com-
plement and coagulation cascades, peroxisome proliferator-
activated receptor (PPAR) signaling, linoleic acid, and mul-
tiple metabolic pathways. Following PAINT analysis, over-
represented promoter elements discovered include jun onco-
gene, hepatocyte nuclear factors 1 and 4 (Hnf1 andHnf4), and
nuclear factor of kappa light polypeptide gene enhancer in B
cells (Nf𝜅B), many of which support liver function.
The probe set IDs (ordered according to pathway), gene
names, symbols, and the fold change between LPC andDL for
clusters A, C, andD are displayed in Supplementary Tables 3–
5. A summary of the promoter elements for these clusters is
available as Supplementary Table 6.
3.3. The LPC Transcriptomic Profile Reveals Known and Novel
Marker Genes. To identify individual genes representative of
LPCs, probe sets corresponding to known or widely used
LPCmarkers were selected.These included A6 actin-binding
protein, alpha fetoprotein, albumin, CD34 antigen, keratins
7, 8, 14, 18, and 19, c-kit oncogene, Cx32 and Cx43 gap
junction proteins, Delta-like 1 homolog, gamma glutamyl
transferase 1, pyruvate kinase isoenzyme typeM2, glutathione
S-transferase, ataxin 1, epithelial cadherin, and neural cell
adhesion molecule [25, 42–45]. Pearson correlation coeffi-
cients were calculated for comparisons between the above
probe sets and each of those in Figure 2. This provided a
statistical relationship between the known LPC markers and
the total list of differentially expressed probe sets in LPCs and
produced a list of 355 sets with a correlation >0.9.
These probe sets were hierarchically clustered to visualize
expression patterns in various tissue types (Figure 4(a)).
Figure 4(a) data is provided as a supplementary spreadsheet
(Figure 4A Matrix). Although all probe sets correlated with
LPC markers, not all are highly expressed in LPCs. This
can be explained as LPC markers include a mixture of
hepatocyte and cholangiocyte markers, which may not be
expressed by all types of LPCs. Figure 4(b) is a magnification
of an area of interest highlighted in yellow in Figure 4(a).
We focused on LPC and DL tissues since diagnostically it
is most beneficial for LPCs to be genetically distinguished
from DL. As expected from the PCA, HCC samples are
interspersed within the DL arrays (Figure 4(b)). Interestingly
LPCs share some common expression patterns with HCC
samples, perhaps indicative of their tumorigenic potential. To
further investigate this, probe sets with low expression in DL
but at least two-fold greater expression in HCC and LPC cat-
egories were identified. These were then compared to genes
displaying a similar expression pattern within hepatocytes,
fibrolamellar HCCs, and hepatoblasts by Oikawa et al. [27]
(SupplementaryTable 7).Wedesignated the distinct clustered
groupings in Figure 4(b): 𝛼, 𝛽, and 𝛾. Group 𝛼 probe sets have
low expression in LPCs, whilst those in groups 𝛽 and 𝛾 are
highly expressed.
Lastly, to generate a list of LPC-expressed genes, the
355 probe sets of Figure 4(a) were refined by retaining only
those that were present in at least 9 of the 10 averaged LPC
microarrays. This filtering yielded 40 probe sets annotated to
34 unique genes, shown in Table 1 including 8 genes that have
been previously associated with LPCs.

















Complement and coagulation cascades
Drug metabolism, cytochrome P450
Retinol metabolism
Drug metabolism, other enzymes
Metabolism of xenobiotics by . . .
























































KEGG pathway Counts/pathway total
3.40E − 03
p value
Figure 3: Probe set clusters A, C, and D contain pathways that are overrepresented in LPCs and liver tissue. Clusters A and C contain probe
sets that are upregulated in liver progenitor cells (LPCs) and cluster D contains those that are upregulated in developed liver whilst being low
in LPCs. The Database for Annotation, Visualization and Integrated Discovery online tool was used to identify overrepresented pathways
(𝑝 < 0.05) within each of these clusters. Pathways are displayed together with the number of genes from the cluster list (counts), the total that
belongs to each pathway (pathway total) and corresponding 𝑝 values.
8 Stem Cells International
Table 1:Markers for liver progenitor cells (LPCs): expression profiles that correlate closely with known LPCmarkers weremined for potential
marker genes. Gene symbol, title, and transcript abundance fold change in LPCs relative to developed liver (DL). References to studies that
identified genes as LPC markers are included where applicable.
Gene symbol Gene title Fold change (LPC/DL) References
Abcc1 ATP-binding cassette, subfamily C (CFTR/MRP) 1 152 [73]
Aldh18a1 Aldehyde dehydrogenase 18 family, member A1 66.1
Capg Capping protein (actin filament), gelsolin-like 82.6
Cdc20 Cell division cycle 20 homolog (S. cerevisiae) 16.5
Enah Enabled homolog (Drosophila) Not expressed in DL [68, 76]
Fhl2 Four and a half LIM domains 2 Not expressed in DL [68]
Gdpd1 Glycerophosphodiester phosphodiesterase domain 1 140
Gnb5 Guanine nucleotide binding protein (G protein), beta 5 92.3
Gpr177 G protein-coupled receptor 177 107
Hs2st1 Heparan sulfate 2-O-sulfotransferase 1 Not expressed in DL
Ift57 Intraflagellar transport 57 homolog (Chlamydomonas) 29.8
Klf5 Kruppel-like factor 5 506 [68]
Ltbp3 Latent transforming growth factor beta binding protein 3 Not expressed in DL
Luzp1 Leucine zipper protein 1 77.7
Map4k4 Mitogen-activated protein kinase kinase kinase kinase 4 34.2 [77]
Mcm2 Minichromosome maintenance deficient 2 8.53
Ncam1 Neural cell adhesion molecule 1 Not expressed in DL [78]
Ndrg4 N-myc downstream regulated gene 4 146
Npnt Nephronectin 83.4
Nup93 Nucleoporin 93 10.3
Nxn Nucleoredoxin 16.9 [76]
Panx1 Pannexin 1 Not expressed in DL
Pfkp Phosphofructokinase, platelet Not expressed in DL
Phc1 Polyhomeotic-like 1 (Drosophila) Not expressed in DL
Pkia Protein kinase inhibitor, alpha Not expressed in DL
Pkm2 Pyruvate kinase, muscle 115 [79]
Plod2 Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 Not expressed in DL
Pmm1 Phosphomannomutase 1 68.2
Prkg2 Protein kinase, cGMP-dependent, type II Not expressed in DL
Sfxn3 Sideroflexin 3 92.5
Tnnt2 Troponin T2, cardiac Not expressed in DL
Tubb2b Tubulin, beta 2b 818
Tulp3 Tubby-like protein 3 Not expressed in DL
Wisp1 WNT1 inducible signaling pathway protein 1 69.0
3.4. Identified Markers Detect LPCs in Injured Liver Tissue
and Their Expression Levels Correlate with LPC Numbers.
For detection of LPCs within a liver sample, genes from
group 𝛼 should display low expression, whilst genes from
groups 𝛽 and 𝛾 should exhibit high expression, relative to
a reference gene. An ideal reference gene should have little
to no variability across a variety of tissue types, and thus
it should have a low coefficient of variation. Taf4a on the
Affymetrix Mouse Genome 430 2.0 chip fits this criterion.
To determine whether a combination of selected genes
from groups 𝛼, 𝛽, and 𝛾 could accurately detect the presence
and abundance of LPCs in liver tissue of varying pathologies
we obtained the livers of mice subjected to the CDE diet,
the immune-mediated Met-Kb and 178.3 transgenic mouse
models, and DDC induced hepatotoxicity. The histology
of these livers showed varying degrees of disease severity
(Figure 5). CDE liver samples displayed steatosis (Figure 5(b),
arrowheads) and numerous small basophilic cells with oval-
shaped nuclei (Figure 5(b), arrows) indicative of LPCs. The
DDC liver featured porphyrin accumulations (Figure 5(d),
arrowheads) and ductular reactions (Figure 5(d), arrows),
whilst the 178.3 liver (Figure 5(f)) displayed normal archi-
tecture and Met-Kb liver showed increased ductal structures
surrounded by many small basophilic cells (Figure 5(h),
arrows). The degree of LPC induction was determined by
staining and quantification of panCK positivity (Figures 5(a),
5(c), 5(e), and 5(g)), found to be 3.3%, 2.5%, 0.09%, and 0.11%
for CDE, DDC, 178.3, and Met-Kb models, respectively.
From our LPC gene signature Ltbp3 and Ncam1 from
group 𝛽 and Mcm2 and M2pk from group 𝛾 displayed the






























Figure 4: Distinct expression profiles for liver progenitor cells
identify three gene expression groups. (a) Hierarchical clustering of
expression profiles that correlate with known liver progenitor cell
markers. (b) Close view of the yellowhighlighted rows from (a), with
particular focus on the LPC and developed liver groupings. Three
distinct groups of gene expression patterns (𝛼, 𝛽, and 𝛾) are defined.
highest abundance in livers of mice on diets yielding the
greatest proportion of panCK positivity (Figure 6). Protein
expression of NCAM1 isoform 140 and M2PK was increased
in 75% CDE diet livers relative to controls, as determined
by Western blot (Supplementary Figure 1). No clear pattern
was observed within NCAM1 isoform 180. The group 𝛼 gene
Murc that is expressed at low levels in LPCs and DL showed
decreased expression in DDC, Met-Kb, and 178.3 liver but
surprisingly was increased in CDE liver (Figure 6).
To confirm that transcript abundance of genes in groups
𝛽 and 𝛾 correlates with LPC number, we quantified the LPC
response in day 0 (𝑛 = 7) and day 21 (𝑛 = 11) mouse CDE
livers (Figure 7). LPC quantitation for all samples ranged
between 0.0036% (Figure 7(a)) and 3.7% (Figure 7(b)). Pre-
dictably, mRNA levels for an established LPC marker Cd24a
strongly correlated (𝑟2 = 0.8810) with panCK positivity
(Figure 7(e)). Importantly, expression ofNcam1 (group𝛽) and
Mcm2 (group 𝛾) also correlated well (𝑟2 = 0.6952 and 0.8128,
resp.) with panCK staining (Figures 7(c) and 7(d)). Collec-
tively these results validate our approach to identify novel
LPC markers that can be used for their detection in vivo and
their utility to assess liver pathology with respect to the extent
of LPC induction.
4. Discussion
In this study we demonstrate that it is possible to collect,
analyze, and compare publicly available transcriptome data
to derive useful information relating to a particular cell type
of interest, in this instance, LPCs. This is possible so long
as appropriate criteria for their inclusion are adopted, and
it is important to use related microarray platforms with a
minimum of three highly correlated replicates and consistent
data normalization. Adherence to these principles benefited
this study as it integrated more than 400 microarrays to
highlight a unique transcriptomic signature of LPCs.
PCA successfully separated LPCs from other stem cell
types and more importantly from other liver cell and tissue
samples. Notably, LPC lines from different research groups,
including array data from a BMEL line derived in Paris
and analyzed in Houston [46], T-LPC isolated in Tokyo
[22] and analyzed in Perth, and other lines isolated and
analyzed in Perth, were more similar to each other than
to other tissue or cell types. Spatially, the LPC cluster is
distant from DL, not surprising considering their different
functions and degree of differentiation. Given the association
between LPCs andHCC, closer clustering of these two groups
could be expected. However, the LPC and HCC clusters are
distant, indicating these HCCs may not be derived from
LPCs. Indeed one of the five HCC analyses used in this
studymentions that the tumors aremostly well-differentiated
[47]. In this case we would expect the HCC group to cluster
closer to the DL group than the LPC one, as reported in
this study. Unfortunately, there is limited or no information
available regarding the differentiated status of the remaining
four HCCs used [48, 49]. Histologically, poorly differentiated
HCCs often carry LPC and/or stem markers [50, 51] and
may be more indicative of LPC-derived HCC. Use of these
types of tumors may have offered further insights into the
relationship between LPCs and LPC-derivedHCC.Moreover
LPCs cluster closely with embryonic liver due to their shared
plasticity and origin. In fact the BMEL LPC line used was
derived from embryonic liver. The proximity of LPCs to
muscle is unexpected, though it may be a result of their
shared immortalized progenitor cell status. LPCs and C2C12
myoblasts used in this study represent immature cells of
their respective lineages and are both involved with tissue
regeneration. Comparison of primary LPCs and muscle cells
may have prevented this association. Despite this, our use
of immortalized cell lines yielded a transcriptomic signature
consistent with LPC biology and genetics.
Notably, overrepresented pathways in cluster D, which
were poorly expressed in LPCs but highly expressed in
developed liver, were consistent with liver functions includ-
ing drug, vitamin, and fatty acid metabolism. Furthermore
upregulated LPC pathways in clusters A and C are consistent
with transcriptomic analyses of rat oval cells [52]. These
LPC pathways included the Wnt, ErbB, p53, MAPK, and
TGF-beta signaling pathways.Wnt/𝛽-catenin is amediator of
LPC activation and expansion [53]. Wnt induced 𝛽-catenin





Figure 5: Four liver injury models display different degrees of pathology and liver progenitor cell (LPC) response. Liver sections from wild-
type mice subjected to a choline-deficient, ethionine-supplemented (CDE; (a) and (b)) or 3,5-diethoxy-carbonyl-1,4-dihydrocollidine (DDC;
(c) and (d)) diet, or transgenic 178.3 ((e) and (f)) or Met-Kb ((g) and (h)) mice were stained with panCK ((a), (c), (e), and (g)) or H&E ((b),
(d), (f), and (h)). Arrows in panels (b) and (d) and (h) indicate LPCs, ductular reactions, and small basophilic cells, respectively. Arrowheads
in panels (b) and (d) indicate steatosis and porphyrin accumulations, respectively. Scale bars represent 100 𝜇m.
phosphorylation targets the gene promoters of EGF, cyclin D
(Ccnd1), fos-like antigen 1 (Fosl1), and c-Myc, to drive cellular
proliferation [54, 55]. Consistently, in cluster A Ccnd1 and
Fosl1 were upregulated in LPCs. Furthermore, activation of
cancer-related processes throughMyc and Ccnd1 and matrix
metalloproteinases have been identified [56] and increased
𝛽-catenin expression has been reported in HCC [57] and
aggressive hepatoblastomas [58].
The ErbB signaling pathway affects diverse cellular func-
tions including proliferation, angiogenesis, migration, and
differentiation. An ErbB2 overexpressing transgenic mouse
exhibits increased numbers of LPC-like cells in the liver
[59], and increased expression of ErbB family members is
reported in a high proportion of humanHCCs and correlates
with cancer progression [60]. These findings support the
integral role of the ErbB family in liver carcinogenesis. It is
widely accepted that aberrant p53 signaling participates in
the development of HCC [61]. Moreover theMAPK signaling
pathway is associated with tumorigenesis via regulation of
proliferation, differentiation, survival, and migration [62].
Finally, increased TGF-beta signaling is critical in inhibition
of hepatocyte-mediated regeneration [63], promoting LPC-
mediated regeneration instead [64]. These results highlight
LPCs as a regenerative cell source for the liver but also as a
putative cancer stem cell that may give rise to HCC [53, 65].
The individual LPC genes identified in this study (Table 1)
also reflect LPC function. Mcm2 is expressed in a variety of
regenerative cells including neural stem cells and hepatocytes
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Figure 6: A liver progenitor cell (LPC) transcriptomic signature can identify liver injurymodels with LPC induction. qPCR-generatedmRNA
expression levels of known (Cd24a and Sox9) and identified (group 𝛼,Murc; 𝛽, Ncam1 and Ltbp3; and 𝛾,Mcm2 andM2pk) LPC markers in
four different liver injury models. Data are normalized to gene expression in the appropriate control livers (indicated by the dotted line) and
are relative to the Taf4a housekeeping gene. Data represents mean + SEM of 3 separate qPCR assays with significance determined by Student’s
𝑡-test (∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001).
[66, 67]. Fhl2, Klf5, and Enah are highly expressed in rat
embryonic hepatoblasts relative to adult hepatocytes [68]
and Fhl2 is a marker of progenitor cells of myeloid [69],
myocardial [70], and mesenchymal [71] origin. Ndrg4 is a
gene involved in cell cycle progression and survival [72].
Abcc1 is highly expressed in stem-like cells within HCC cell
lines and confers chemotherapeutic resistance, a property of
HCC [73].
In this study we were able to use genes from our LPC
signature to successfully reflect the presence or absence of
LPCs in a number of liver injury models. The unexpected
expression of the group 𝛼 gene, Murc, in CDE liver may be
explained by the presence of activated hepatic stellates in
this model [74], since they are known to express Murc [75].
Consequently, we found expression of individual genes from
either group 𝛽 or group 𝛾 was more reliable for detection
of LPCs in tissue samples than a signature encompassing all
three groups.
Our approach has identified many novel LPC markers,
useful for detection of these cells in vivo. Markers that are
expressed on the cell surface have the potential for isolating
LPCs. According to their gene ontology, the novel LPC
markers GNBP5, PANX1, PRKG2, and TULP3 from Table 1
localize to the plasmamembrane; however this would need to
be confirmed using fluorescence microscopy and subcellular
fractionation.
5. Conclusion
Using publicly available gene expression/microarray data,
we compare the LPC transcriptome against other cell and
tissue types and identify signaling pathways that support
their ability to rapidly proliferate and differentiate. We find
pathways which are consistent with their putative role as
a cancer stem cell in HCC. Importantly we also identify
many novel LPCmarkers, several of which localize to the cell
membrane.This is beneficial for the field as there is a scarcity
of specific markers that can both identify and purify LPCs.
Finally, since LPCsmay reflect a precancerous liver condition
as well as the severity for a range of liver pathologies, our LPC
signature could ideally be used as a novel early indicator of
liver disease in patients.
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Figure 7: Gene expression of group 𝛽 and 𝛾 genes, Ncam1 and Mcm2, and the known marker Cd24a correlate with panCK staining in
vivo. Representative images of (a) control and (b) choline-deficient, ethionine-supplemented (CDE) mouse liver sections stained for panCK.
Expressions of (c) Ncam1, (d) Mcm2, and (e) Cd24a relative to Taf4a in a variety of CDE and control liver tissues are plotted against their
corresponding panCK positivity values.
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